Loading...

Biocartis Group NV

BCART.BREURONEXT
Healthcare
Medical - Diagnostics & Research
0.29
0.00(0.00%)
U.S. Market opens in 5h 25m

Biocartis Group NV (BCART.BR) Stock Competitors & Peer Comparison

See (BCART.BR) competitors and their performances in Stock Market.

Peer Comparison Table: Medical - Diagnostics & Research Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
BCART.BR€0.29+0.00%27.2M-0.32-€0.92N/A
ERF.PA€61.48-0.52%11B24.35€2.55+0.97%
BIM.PA€89.95+0.33%10.5B26.77€3.34+1.01%
LBIRD.PA€20.00-2.91%442.6M41.88€0.48N/A
MDXH.BR€3.02-3.76%85.6M-1.58-€1.91N/A
ALECR.PA€16,100.00+0.00%81.2M13.17€1,222.20N/A
ALBIO.PA€0.80-4.76%14.7M-0.20-€3.98N/A
ALPRE.PA€3.09+0.00%12.1M-2.92-€1.06N/A
EEP.MC€0.54N/A6.2M-54.00-€0.01N/A
MLAHC.PA€0.60+0.00%5.4M-10.00-€0.06N/A
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

BCART.BR vs ERF.PA Comparison April 2026

BCART.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BCART.BR stands at 27.2M. In comparison, ERF.PA has a market cap of 11B. Regarding current trading prices, BCART.BR is priced at €0.29, while ERF.PA trades at €61.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BCART.BR currently has a P/E ratio of -0.32, whereas ERF.PA's P/E ratio is 24.35. In terms of profitability, BCART.BR's ROE is +2.04%, compared to ERF.PA's ROE of +0.12%. Regarding short-term risk, BCART.BR is more volatile compared to ERF.PA. This indicates potentially higher risk in terms of short-term price fluctuations for BCART.BR.Check ERF.PA's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions